Contributions of computational chemistry and biophysical techniques to fragment-based drug discovery

Current Medicinal Chemistry

Volumn 17, Issue 17, 2010, Pages 1769-1794

  Gozalbes, Rafael ^a   Carbajo, Rodrigo J ^a   Pineda Lucena, Antonio ^a  

^a CENTRO DE INVESTIGACIÓN PRÍNCIPE FELIPE   (Spain)

Author keywords

Computational chemistry; Fluorescence based thermal shift assay; Fragment based screening; Isothermal titration calorimetry; Mass spectrometry; Nuclear magnetic resonance spectroscopy; Surface plasmon resonance; X ray crystallography

Indexed keywords

NEW DRUG;

ARTICLE; BIOPHYSICS; CHEMISTRY; COMPUTATIONAL CHEMISTRY; DATA ANALYSIS SOFTWARE; DATA BASE; DRUG DEVELOPMENT; FRAGMENT BASED DRUG DISCOVERY; HIGH THROUGHPUT SCREENING; ISOTHERMAL TITRATION CALORIMETRY; MASS SPECTROMETRY; MOLECULAR DOCKING; MOLECULAR LIBRARY; NUCLEAR MAGNETIC RESONANCE; PHARMACOPHORE; PHYSICAL CHEMISTRY; SOLUBILITY; SURFACE PLASMON RESONANCE; X RAY CRYSTALLOGRAPHY;

BIOPHYSICS; COMPUTATIONAL BIOLOGY; CRYSTALLOGRAPHY, X-RAY; DRUG DISCOVERY; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SURFACE PLASMON RESONANCE;

EID: 77953530689     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710791111224     Document Type: Article

References (246)

1. Bohacek, R.S.; McMartin, C.; Guida, W.C. The art and practice of structure-based drug design: a molecular modeling perspective. Med. Res. Rev., 1996, 16, 3-50.
2. Fox, S.; Wang, H.; Sopchak, L.; Khoury, R. High throughput screening: early successes indicate a promising future. J. Biomol. Screen., 2001, 6, 137-140.
3. Hann, M.M.; Leach, A.R.; Harper, G. Molecular complexity and its impact on the probability of finding leads for drug discovery. J. Chem. Inf. Comput. Sci., 2001, 41, 856-864.
4. Johnston, K.A. Chemical attraction: affinity techniques aid in new drug discovery. Pharma Genomics, 2001, 28, 30-39.
5. Gribbon, P.; Sewing, A. Fluorescence readouts in HTS: no gain without pain? Drug Discov. Today, 2003, 8, 1035-1043.
6. Clark, M. Generalized fragment-substructure based property prediction method. J. Chem. Inf. Model., 2005, 45, 30-38.
7. Patlewicz, G.; Rodford, R.; Walker, J.D. Quantitative structureactivity relationships for predicting mutagenicity and carcinogenicity. Environ. Toxicol. Chem., 2003, 22, 1885-1893.
8. Hubbard, R.E.; Chen, I.; Davis, B. Informatics and modeling challenges in fragment-based drug discovery. Curr. Opin. Drug Discov. Devel., 2007, 10, 289-297.
9. Villar, H.O.; Hansen, M.R. Computational techniques in fragment based drug discovery. Curr. Top. Med. Chem., 2007, 7, 1509-1513.
10. Law, R.; Barker, O.; Barker, J.J.; Hesterkamp, T.; Godemann, R.; Andersen, O.; Fryatt, T.; Courtney, S.; Hallett, D.; Whittaker, M. The multiple roles of computational chemistry in fragment-based drug design. J. Comput. Aided Mol. Des., 2009, 23, 459-473.
11. Zoete, V.; Grosdidier, A.; Michielin, O. Docking, virtual high throughput screening and in silico fragment-based drug design. J. Cell. Mol. Med., 2009, 13, 238-248.
12. Lepre, C.A. Library design for NMR-based screening. Drug Discov. Today, 2001, 6, 133-140.
13. Congreve, M.; Chessari, G.; Tisi, D.; Woodhead, A.J. Recent developments in fragment-based drug discovery. J. Med. Chem., 2008, 51, 3661-3680.
14. Blomberg, N.; Cosgrove, D.A.; Kenny, P.W.; Kolmodin, K. Design of compound libraries for fragment screening. J. Comput. Aided Mol. Des., 2009, 23, 513-525.
15. Baurin, N.; Aboul-Ela, F.; Barril, X.; Davis, B.; Drysdale, M.; Dymock, B.; Finch, H.; Fromont, C.; Richardson, C.; Simmonite, H.; Hubbard, R.E. Design and characterization of libraries of molecular fragments for use in NMR screening against protein targets. J. Chem. Inf. Comput. Sci., 2004, 44, 2157-2166.
16. Lipinski, C.; Hopkins, A. Navigating chemical space for biology and medicine. Nature, 2004, 432, 855-861.
17. Van Drie, J.H.; Lajiness, M.E. Approaches to virtual library design. Drug Discov. Today, 1998, 3, 274-283.
18. Willett, P. Similarity-based virtual screening using 2D fingerprints. Drug Discov. Today, 2006, 11, 1046-1053.
19. Flower, D.R. DISSIM: a program for the analysis of chemical diversity. J. Mol. Graph. Model., 1998, 16, 239-253, 264.
20. Bayada, D.M.; Hamersma, H.; van Geerestein, V.J. Molecular Diversity and Representativity in Chemical Databases. J. Chem. Inf. Comput. Sci., 1999, 39, 1-10.
21. Cramer, R.D.; Clark, R.D.; Patterson, D.E.; Ferguson, A.M. Bioisosterism as a molecular diversity descriptor: steric fields of single topomeric conformers. J. Med. Chem., 1996, 39, 3060-3069.
22. Horvath, D.; Jeandenans, C. Neighborhood behavior of in silico structural spaces with respect to in vitro activity spaces--a bench-mark for neighborhood behavior assessment of different in silico similarity metrics. J. Chem. Inf. Comput. Sci., 2003, 43, 691-698.
23. Patterson, D.E.; Cramer, R.D.; Ferguson, A.M.; Clark, R.D.; Weinberger, L.E. Neighborhood behavior: a useful concept for validation of molecular diversity descriptors. J. Med. Chem., 1996, 39, 3049-3059.
24. Gozalbes, R.; Doucet, J.P.; Derouin, F. Application of topological descriptors in QSAR and drug design: history and new trends. Curr. Drug Targets Infect. Disord., 2002, 2, 93-102.
25. Lewis, R.A.; Mason, J.S.; McLay, I.M. Similarity measures for rational set selection and analysis of combinatorial libraries: the Diverse Property-Derived (DPD) approach. J. Chem. Inf. Comput. Sci., 1997, 37, 599-614.
26. Bergmann, R.; Linusson, A.; Zamora, I. SHOP: scaffold HOPping by GRID-based similarity searches. J. Med. Chem., 2007, 50, 2708-2717.
27. Krier, M.; Bret, G.; Rognan, D. Assessing the scaffold diversity of screening libraries. J. Chem. Inf. Model., 2006, 46, 512-524.
28. Martin, E.J.; Critchlow, R.E. Beyond mere diversity: tailoring combinatorial libraries for drug discovery. J. Comb. Chem., 1999, 1, 32-45.
29. Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev., 2001, 46, 3-26.
30. Monge, A.; Arrault, A.; Marot, C.; Morin-Allory, L. Managing, profiling and analyzing a library of 2.6 million compounds gathered from 32 chemical providers. Mol. Divers., 2006, 10, 389-403.
31. Teague, S.J.; Davis, A.M.; Leeson, P.D.; Oprea, T. The Design of Leadlike Combinatorial Libraries. Angew. Chem. Int. Ed. Engl., 1999, 38, 3743-3748.
32. Congreve, M.; Carr, R.; Murray, C.; Jhoti, H. A 'rule of three' for fragment-based lead discovery? Drug Discov. Today, 2003, 8, 876-877.
33. Carr, R.A.E.; Congreve, M.; Murray, C.W.; Rees, D.C. Fragmentbased lead discovery: leads by design. Drug Discov. Today, 2005, 10, 987-992.
34. Fejzo, J.; Lepre, C.A.; Peng, J.W.; Bemis, G.W.; Ajay; Murcko, M.A.; Moore, J.M. The SHAPES strategy: an NMR-based approach for lead generation in drug discovery. Chem. Biol., 1999, 6, 755-769.
35. Bemis, G.W.; Murcko, M.A. The properties of known drugs. 1. Molecular frameworks. J. Med. Chem., 1996, 39, 2887-2893.
36. Kolb, P.; Caflisch, A. Automatic and efficient decomposition of two-dimensional structures of small molecules for fragment-based high-throughput docking. J. Med. Chem., 2006, 49, 7384-7392.
37. Walters, W.P.; Stahl, M.T.; Murcko, M.A. Virtual screening an overview. Drug Discov. Today, 1998, 3, 160-178.
38. Hopkins, A.L.; Groom, C.R.; Alex, A. Ligand efficiency: a useful metric for lead selection. Drug Discov. Today, 2004, 9, 430-431.
39. Abad-Zapatero, C.; Metz, J.T. Ligand efficiency indices as guideposts for drug discovery. Drug Discov. Today, 2005, 10, 464-469.
40. Reynolds, C.H.; Bembenek, S.D.; Tounge, B.A. The role of molecular size in ligand efficiency. Bioorg. Med. Chem. Lett., 2007, 17, 4258-4261.
41. Bembenek, S.D.; Tounge, B.A.; Reynolds, C.H. Ligand efficiency and fragment-based drug discovery. Drug Discov. Today, 2009, 14, 278-283.
42. Lamanna, C.; Bellini, M.; Padova, A.; Westerberg, G.; Maccari, L. Straightforward recursive partitioning model for discarding insoluble compounds in the drug discovery process. J. Med. Chem., 2008, 51, 2891-2897.
43. Kerns, E.H.; Di, L.; Carter, G.T. In vitro solubility assays in drug discovery. Curr. Drug Metab., 2008, 9, 879-885.
44. Colclough, N.; Hunter, A.; Kenny, P.W.; Kittlety, R.S.; Lobedan, L.; Tam, K.Y.; Timms, M.A. High throughput solubility determination with application to selection of compounds for fragment screening. Bioorg. Med. Chem., 2008, 16, 6611-6616.
45. Delaney, J.S. Predicting aqueous solubility from structure. Drug Discov. Today, 2005, 10, 289-295.
46. Faller, B.; Ertl, P. Computational approaches to determine drug solubility. Adv. Drug Deliv. Rev., 2007, 59, 533-545.
47. Llinas, A.; Glen, R.C.; Goodman, J.M. Solubility challenge: can you predict solubilities of 32 molecules using a database of 100 reliable measurements? J. Chem. Inf. Model., 2008, 48, 1289-1303.
48. Hopfinger, A.J.; Esposito, E.X.; Llinas, A.; Glen, R.C.; Goodman, J.M. Findings of the challenge to predict aqueous solubility. J. Chem. Inf. Model., 2009, 49, 1-5.
49. Schneider, G.; Neidhart, W.; Giller, T.; Schmid, G. Scaffold-Hopping by topological pharmacophore search: a contribution to virtual screening. Angew. Chem. Int. Ed. Engl., 1999, 38, 2894-2896.
50. Baber, J.C.; Feher, M. Predicting synthetic accessibility: application in drug discovery and development. Mini Rev. Med. Chem., 2004, 4, 681-692.
51. Lewell, X.Q.; Judd, D.B.; Watson, S.P.; Hann, M.M. RECAP-retrosynthetic combinatorial analysis procedure: a powerful new technique for identifying privileged molecular fragments with useful applications in combinatorial chemistry. J. Chem. Inf. Comput. Sci., 1998, 38, 511-522.
52. Vinkers, H.M.; de Jonge, M.R.; Daeyaert, F.F.; Heeres, J.; Koymans, L.M.; van Lenthe, J.H.; Lewi, P.J.; Timmerman, H.; Van Aken, K.; Janssen, P.A. SYNOPSIS: SYNthesize and optimize system in silico. J. Med. Chem., 2003, 46, 2765-2773.
53. Vieth, M.; Siegel, M.G.; Higgs, R.E.; Watson, I.A.; Robertson, D.H.; Savin, K.A.; Durst, G.L.; Hipskind, P.A. Characteristic physical properties and structural fragments of marketed oral drugs. J. Med. Chem., 2004, 47, 224-232.
54. Boda, K.; Seidel, T.; Gasteiger, J. Structure and reaction based evaluation of synthetic accessibility. J. Comput. Aided Mol. Des., 2007, 21, 311-325.
55. Moore, J.; Abdul-Manan, N.; Fejzo, J.; Jacobs, M.; Lepre, C.; Peng, J.; Xie, X. Leveraging structural approaches: applications of NMR-based screening and X-ray crystallography for inhibitor design. J. Synchrotron Radiat., 2004, 11, 97-100.
56. Shuker, S.B.; Hajduk, P.J.; Meadows, R.P.; Fesik, S.W. Discovering high-affinity ligands for proteins: SAR by NMR. Science, 1996, 274, 1531-1534.
57. Oltersdorf, T.; Elmore, S.W.; Shoemaker, A.R.; Armstrong, R.C.; Augeri, D.J.; Belli, B.A.; Bruncko, M.; Deckwerth, T.L.; Dinges, J.; Hajduk, P.J.; Joseph, M.K.; Kitada, S.; Korsmeyer, S.J.; Kunzer, A.R.; Letai, A.; Li, C.; Mitten, M.J.; Nettesheim, D.G.; Ng, S.; Nimmer, P.M.; O'Connor, J.M.; Oleksijew, A.; Petros, A.M.; Reed, J.C.; Shen, W.; Tahir, S.K.; Thompson, C.B.; Tomaselli, K.J.; Wang, B.; Wendt, M.D.; Zhang, H.; Fesik, S.W.; Rosenberg, S.H. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature, 2005, 435, 677-681.
58. Rohrig, C.H.; Loch, C.; Guan, J.Y.; Siegal, G.; Overhand, M. Fragment-based synthesis and SAR of modified FKBP ligands: influence of different linking on binding affinity. ChemMedChem, 2007, 2, 1054-1070.
59. Eisen, M.B.; Wiley, D.C.; Karplus, M.; Hubbard, R.E. HOOK: a program for finding novel molecular architectures that satisfy the chemical and steric requirements of a macromolecule binding site. Proteins, 1994, 19, 199-221.
60. Miranker, A.; Karplus, M. Functionality maps of binding sites: a multiple copy simultaneous search method. Proteins, 1991, 11, 29-34.
61. Schubert, C.R.; Stultz, C.M. The multi-copy simultaneous search methodology: a fundamental tool for structure-based drug design. J. Comput. Aided Mol. Des., 2009, 23, 475-489.
62. Imai, T.; Oda, K.; Kovalenko, A.; Hirata, F.; Kidera, A. Ligand mapping on protein surfaces by the 3D-RISM theory: toward computational fragment-based drug design. J. Am. Chem. Soc., 2009, 131, 12430-12440.
63. Boehm, H.J.; Boehringer, M.; Bur, D.; Gmuender, H.; Huber, W.; Klaus, W.; Kostrewa, D.; Kuehne, H.; Luebbers, T.; Meunier-Keller, N.; Mueller, F. Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening. J. Med. Chem., 2000, 43, 2664-2674.
64. Edwards, P.D.; Albert, J.S.; Sylvester, M.; Aharony, D.; Andisik, D.; Callaghan, O.; Campbell, J.B.; Carr, R.A.; Chessari, G.; Congreve, M.; Frederickson, M.; Folmer, R.H.; Geschwindner, S.; Koether, G.; Kolmodin, K.; Krumrine, J.; Mauger, R.C.; Murray, C.W.; Olsson, L.L.; Patel, S.; Spear, N.; Tian, G. Application of fragment-based lead generation to the discovery of novel, cyclic amidine beta-secretase inhibitors with nanomolar potency, cellular activity, and high ligand efficiency. J. Med. Chem., 2007, 50, 5912-5925.
65. Bohm, H.J. The computer program LUDI: a new method for the de novo design of enzyme inhibitors. J. Comput. Aided Mol. Des., 1992, 6, 61-78.
66. Clark, D.E.; Frenkel, D.; Levy, S.A.; Li, J.; Murray, C.W.; Robson, B.; Waszkowycz, B.; Westhead, D.R. PRO-LIGAND: an approach to de novo molecular design. 1. Application to the design of organic molecules. J. Comput. Aided Mol. Des., 1995, 9, 13-32.
67. DeWitte, R.S.; Shakhnovich, E.I. SMoG: de Novo design method based on simple, fast, and accurate free energy estimates. 1. Methodology and supporting evidence. J. Am. Chem. Soc., 1996, 118, 11733-11744.
68. Wang, R.; Gao, Y.; Lai, L. LigBuilder: a multipurpose program for structure-based drug design. J. Mol. Model., 2000, 6, 498-516.
69. Murray, C.W.; Clark, D.E.; Auton, T.R.; Firth, M.A.; Li, J.; Sykes, R.A.; Waszkowycz, B.; Westhead, D.R.; Young, S.C. PRO_SELECT: combining structure-based drug design and combinatorial chemistry for rapid lead discovery. 1. Technology. J. Comput. Aided Mol. Des., 1997, 11, 193-207.
70. Liebeschuetz, J.W.; Jones, S.D.; Morgan, P.J.; Murray, C.W.; Rimmer, A.D.; Roscoe, J.M.; Waszkowycz, B.; Welsh, P.M.; Wylie, W.A.; Young, S.C.; Martin, H.; Mahler, J.; Brady, L.; Wilkinson, K. PRO_SELECT: combining structure-based drug design and array-based chemistry for rapid lead discovery. 2. The development of a series of highly potent and selective factor Xa inhibitors. J. Med. Chem., 2002, 45, 1221-1232.
71. Pickett, S.D.; McLay, I.M.; Clark, D.E. Enhancing the hit-to-lead properties of lead optimization libraries. J. Chem. Inf. Comput. Sci., 2000, 40, 263-272.
72. Pierce, A.C.; Rao, G.; Bemis, G.W. BREED: Generating novel inhibitors through hybridization of known ligands. Application to CDK2, p38, and HIV protease. J. Med. Chem., 2004, 47, 2768-2775.
73. Wagener, M.; Lommerse, J.P. The quest for bioisosteric replacements. J. Chem. Inf. Model., 2006, 46, 677-685.
74. Stewart, K.D.; Shiroda, M.; James, C.A. Drug Guru: A computer software program for drug design using medicinal chemistry rules. Bioorg. Med. Chem., 2006, 14, 7011-7022.
75. Warren, G.L.; Andrews, C.W.; Capelli, A.M.; Clarke, B.; LaLonde, J.; Lambert, M.H.; Lindvall, M.; Nevins, N.; Semus, S.F.; Senger, S.; Tedesco, G.; Wall, I.D.; Woolven, J.M.; Peishoff, C.E.; Head, M.S. A critical assessment of docking programs and scoring functions. J. Med. Chem., 2006, 49, 5912-5931.
76. Loving, K.; Salam, N.K.; Sherman, W. Energetic analysis of fragment docking and application to structure-based pharmacophore hypothesis generation. J. Comput. Aided Mol. Des., 2009, 23, 541-554.
77. Teotico, D.G.; Babaoglu, K.; Rocklin, G.J.; Ferreira, R.S.; Giannetti, A.M.; Shoichet, B.K. Docking for fragment inhibitors of AmpC beta-lactamase. Proc. Natl. Acad. Sci. U.S.A., 2009, 106, 7455-7460.
78. Friesner, R.A.; Banks, J.L.; Murphy, R.B.; Halgren, T.A.; Klicic, J.J.; Mainz, D.T.; Repasky, M.P.; Knoll, E.H.; Shelley, M.; Perry, J.K.; Shaw, D.E.; Francis, P.; Shenkin, P.S. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem., 2004, 47, 1739-1749.
79. Kawatkar, S.; Wang, H.; Czerminski, R.; Joseph-McCarthy, D. Virtual fragment screening: an exploration of various docking and scoring protocols for fragments using Glide. J. Comput. Aided Mol. Des., 2009, 23, 527-539.
80. Warner, S.L.; Bashyam, S.; Vankayalapati, H.; Bearss, D.J.; Han, H.; Mahadevan, D.; Von Hoff, D.D.; Hurley, L.H. Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment-based approach. Mol. Cancer Ther., 2006, 5, 1764-1773.
81. Mahadevan, D.; Bearss, D.J.; Vankayalapati, H. Structure-based design of novel anti-cancer agents targeting aurora kinases. Curr. Med. Chem. Anticancer Agents, 2003, 3, 25-34.
82. Nowakowski, J.; Cronin, C.N.; McRee, D.E.; Knuth, M.W.; Nelson, C.G.; Pavletich, N.P.; Rogers, J.; Sang, B.C.; Scheibe, D.N.; Swanson, R.V.; Thompson, D.A. Structures of the cancer-related Aurora-A, FAK, and EphA2 protein kinases from nanovolume crystallography. Structure, 2002, 10, 1659-1667.
83. Hubbard, R.E. Fragment approaches in structure-based drug discovery. J. Synchrotron Radiat., 2008, 15, 227-230.
84. Dymock, B.W.; Barril, X.; Brough, P.A.; Cansfield, J.E.; Massey, A.; McDonald, E.; Hubbard, R.E.; Surgenor, A.; Roughley, S.D.; Webb, P.; Workman, P.; Wright, L.; Drysdale, M.J. Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design. J. Med. Chem., 2005, 48, 4212-4215.
85. Brough, P.A.; Aherne, W.; Barril, X.; Borgognoni, J.; Boxall, K.; Cansfield, J.E.; Cheung, K.M.; Collins, I.; Davies, N.G.; Drysdale, M.J.; Dymock, B.; Eccles, S.A.; Finch, H.; Fink, A.; Hayes, A.; Howes, R.; Hubbard, R.E.; James, K.; Jordan, A.M.; Lockie, A.; Martins, V.; Massey, A.; Matthews, T.P.; McDonald, E.; Northfield, C.J.; Pearl, L.H.; Prodromou, C.; Ray, S.; Raynaud, F.I.; Roughley, S.D.; Sharp, S.Y.; Surgenor, A.; Walmsley, D.L.; Webb, P.; Wood, M.; Workman, P.; Wright, L. 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. J. Med.Chem., 2008, 51, 196-218.
86. Stockman, B.J.; Kothe, M.; Kohls, D.; Weibley, L.; Connolly, B.J.; Sheils, A.L.; Cao, Q.; Cheng, A.C.; Yang, L.; Kamath, A.V.; Ding, Y.H.; Charlton, M.E. Identification of Allosteric PIF-Pocket Ligands for PDK1 using NMR-Based Fragment Screening and H-1-N-15 TROSY Experiments. Chem. Biol. Drug Des., 2009, 73, 179-188.
87. Huang, D.; Caflisch, A. Library screening by fragment-based docking. J. Mol. Recognit., 2010, 23(2), 183-93.
88. DeLano, W.L. Unraveling hot spots in binding interfaces: progress and challenges. Curr. Opin. Struct. Biol., 2002, 12, 14-20.
89. Arkin, M.R.; Wells, J.A. Small-molecule inhibitors of proteinprotein interactions: progressing towards the dream. Nat. Rev. Drug Discov., 2004, 3, 301-317.
90. Ciulli, A.; Williams, G.; Smith, A.G.; Blundell, T.L.; Abell, C. Probing hot spots at protein-ligand binding sites: a fragment-based approach using biophysical methods. J. Med. Chem., 2006, 49, 4992-5000.
91. Vajda, S.; Guarnieri, F. Characterization of protein-ligand interaction sites using experimental and computational methods. Curr. Opin. Drug Discov. Devel., 2006, 9, 354-362.
92. Bondensgaard, K.; Ankersen, M.; Thogersen, H.; Hansen, B.S.; Wulff, B.S.; Bywater, R.P. Recognition of privileged structures by G-protein coupled receptors. J. Med. Chem., 2004, 47, 888-899.
93. Rolland, C.; Gozalbes, R.; Nicolai, E.; Paugam, M.F.; Coussy, L.; Barbosa, F.; Horvath, D.; Revah, F. G-protein-coupled receptor affinity prediction based on the use of a profiling dataset: QSAR design, synthesis, and experimental validation. J. Med. Chem., 2005, 48, 6563-6574.
94. Gozalbes, R.; Simon, L.; Froloff, N.; Sartori, E.; Monteils, C.; Baudelle, R. Development and experimental validation of a docking strategy for the generation of kinase-targeted libraries. J. Med. Chem., 2008, 51, 3124-3132.
95. Doppelt-Azeroual, O.; Moriaud, F.; Adcock, S.A.; Delfaud, F. A review of MED-SuMo applications. Infect. Disord. Drug Targets, 2009, 9, 344-357.
96. Guner, O.F. History and evolution of the pharmacophore concept in computer-aided drug design. Curr. Top Med. Chem., 2002, 2, 1321-1332.
97. Wolber, G.; Seidel, T.; Bendix, F.; Langer, T. Moleculepharmacophore superpositioning and pattern matching in computational drug design. Drug Discov. Today, 2008, 13, 23-29.
98. Wermuth, C.G.; Ganellin, C.R.; Lindberg, P.; Mitscher, L.A. Glossary of terms used in medicinal chemistry (IUPAC Recommendations 1997). Annu. Rep. Med. Chem., 1998, 33, 385-395.
99. Hohwy, M.; Spadola, L.; Lundquist, B.; Hawtin, P.; Dahmen, J.; Groth-Clausen, I.; Nilsson, E.; Persdotter, S.; von Wachenfeldt, K.; Folmer, R.H.; Edman, K. Novel prostaglandin D synthase inhibitors generated by fragment-based drug design. J. Med. Chem., 2008, 51, 2178-2186.
100. Lubbers, T.; Angehrn, P.; Gmunder, H.; Herzig, S. Design, synthesis, and structure-activity relationship studies of new phenolic DNA gyrase inhibitors. Bioorg. Med. Chem. Lett., 2007, 17, 4708-4714.
101. Oblak, M.; Grdadolnik, S.G.; Kotnik, M.; Jerala, R.; Filipic, M.; Solmajer, T. In silico fragment-based discovery of indolin-2-one analogues as potent DNA gyrase inhibitors. Bioorg. Med. Chem. Lett., 2005, 15, 5207-5210.
102. Ji, H.; Stanton, B.Z.; Igarashi, J.; Li, H.; Martasek, P.; Roman, L.J.; Poulos, T.L.; Silverman, R.B. Minimal pharmacophoric elements and fragment hopping, an approach directed at molecular diversity and isozyme selectivity. Design of selective neuronal nitric oxide synthase inhibitors. J. Am. Chem. Soc., 2008, 130, 3900-3914.
103. Ji, H.; Li, H.; Martasek, P.; Roman, L.J.; Poulos, T.L.; Silverman, R.B. Discovery of highly potent and selective inhibitors of neuronal nitric oxide synthase by fragment hopping. J. Med. Chem., 2009, 52, 779-797.
104. Ilan, N.; Elkin, M.; Vlodavsky, I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int. J. Biochem. Cell Biol., 2006, 38, 2018-2039.
105. Gozalbes, R.; Mosulen, S.; Carbajo, R.J.; Pineda-Lucena, A. Development and NMR validation of minimal pharmacophore hypotheses for the generation of fragment libraries enriched in heparanase inhibitors. J. Comput. Aided Mol. Des., 2009, 23, 555-569.
106. Cimmperman, P.; Baranauskiene, L.; Jachimoviciute, S.; Jachno, J.; Torresan, J.; Michailoviene, V.; Matuliene, J.; Sereikaite, J.; Bumelis, V.; Matulis, D. A quantitative model of thermal stabilization and destabilization of proteins by ligands. Biophys. J., 2008, 95, 3222-3231.
107. Lo, M.C.; Aulabaugh, A.; Jin, G.; Cowling, R.; Bard, J.; Malamas, M.; Ellestad, G. Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery. Anal. Biochem., 2004, 332, 153-159.
108. Waldron, T.T.; Murphy, K.P. Stabilization of proteins by ligand binding: application to drug screening and determination of unfolding energetics. Biochemistry, 2003, 42, 5058-5064.
109. Carver, T.E.; Bordeau, B.; Cummings, M.D.; Petrella, E.C.; Pucci, M.J.; Zawadzke, L.E.; Dougherty, B.A.; Tredup, J.A.; Bryson, J.W.; Yanchunas, J., Jr.; Doyle, M.L.; Witmer, M.R.; Nelen, M.I.; DesJarlais, R.L.; Jaeger, E.P.; Devine, H.; Asel, E.D.; Springer, B.A.; Bone, R.; Salemme, F.R.; Todd, M.J. Decrypting the biochemical function of an essential gene from Streptococcus pneumoniae using ThermoFluor technology. J. Biol. Chem., 2005, 280, 11704-11712.
110. Pantoliano, M.W.; Petrella, E.C.; Kwasnoski, J.D.; Lobanov, V.S.; Myslik, J.; Graf, E.; Carver, T.; Asel, E.; Springer, B.A.; Lane, P.; Salemme, F.R. High-density miniaturized thermal shift assays as a general strategy for drug discovery. J. Biomol. Screen., 2001, 6, 429-440.
111. Pantoliano, M.W.; Salemme, F.R.; Carver, T. U.S. Patent Application Serial No. US 2002/0168686 A1, published Nov 14 2002.
112. Matulis, D.; Kranz, J.K.; Salemme, F.R.; Todd, M.J. Thermodynamic stability of carbonic anhydrase: measurements of binding affinity and stoichiometry using ThermoFluor. Biochemistry, 2005, 44, 5258-5266.
113. Grasberger, B.L.; Lu, T.; Schubert, C.; Parks, D.J.; Carver, T.E.; Koblish, H.K.; Cummings, M.D.; LaFrance, L.V.; Milkiewicz, K.L.; Calvo, R.R.; Maguire, D.; Lattanze, J.; Franks, C.F.; Zhao, S.; Ramachandren, K.; Bylebyl, G.R.; Zhang, M.; Manthey, C.L.; Petrella, E.C.; Pantoliano, M.W.; Deckman, I.C.; Spurlino, J.C.; Maroney, A.C.; Tomczuk, B.E.; Molloy, C.J.; Bone, R.F. Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. J. Med. Chem., 2005, 48, 909-912.
114. Sharma, S.K.; Ramsey, T.M.; Bair, K.W. Protein-protein interactions: lessons learned. Curr. Med. Chem. Anticancer Agents, 2002, 2, 311-330.
115. Chene, P. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat. Rev. Cancer, 2003, 3, 102-109.
116. Cummings, M.D.; Farnum, M.A.; Nelen, M.I. Universal screening methods and applications of ThermoFluor. J. Biomol. Screen, 2006, 11, 854-863.
117. Ericsson, U.B.; Hallberg, B.M.; Detitta, G.T.; Dekker, N.; Nordlund, P. Thermofluor-based high-throughput stability optimization of proteins for structural studies. Anal. Biochem., 2006, 357, 289-298.
118. Romanuka, J.; van den Bulke, H.; Kaptein, R.; Boelens, R.; Folkers, G.E. Novel strategies to overcome expression problems encountered with toxic proteins: application to the production of Lac repressor proteins for NMR studies. Protein Expr. Purif., 2009, 67, 104-112.
119. McGovern, S.L.; Caselli, E.; Grigorieff, N.; Shoichet, B.K. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J. Med. Chem., 2002, 45, 1712-1722.
120. McGovern, S.L.; Helfand, B.T.; Feng, B.; Shoichet, B.K. A specific mechanism of nonspecific inhibition. J. Med. Chem., 2003, 46, 4265-4272.
121. McGovern, S.L.; Shoichet, B.K. Kinase inhibitors: not just for kinases anymore. J. Med. Chem., 2003, 46, 1478-1483.
122. Seidler, J.; McGovern, S.L.; Doman, T.N.; Shoichet, B.K. Identification and prediction of promiscuous aggregating inhibitors among known drugs. J. Med. Chem., 2003, 46, 4477-4486.
123. Schuck, P. Use of surface plasmon resonance to probe the equilibrium and dynamic aspects of interactions between biological macromolecules. Annu. Rev. Biophys. Biomol. Struct., 1997, 26, 541-566.
124. Homola, J.; Yee, S.S.; Gauglitz, G. Surface plasmon resonance sensors: review. Sens. Actuators B. Chem., 1999, 54, 3-15.
125. Homola, J. Present and future of surface plasmon resonance biosensors. Anal. Bioanal. Chem., 2003, 377, 528-539.
126. Rich, R.L.; Myszka, D.G. Why you should be using more SPR biosensor technology. Drug Discov. Today Technol., 2004, 1, 301-308.
127. Perspicace, S.; Banner, D.; Benz, J.; Muller, F.; Schlatter, D.; Huber, W. Fragment-based screening using surface plasmon resonance technology. J. Biomol. Screen., 2009, 14, 337-349.
128. Hamalainen, M.D.; Zhukov, A.; Ivarsson, M.; Fex, T.; Gottfries, J.; Karlsson, R.; Bjorsne, M. Label-free primary screening and affinity ranking of fragment libraries using parallel analysis of protein panels. J. Biomol. Screen., 2008, 13, 202-209.
129. Nordstrom, H.; Gossas, T.; Hamalainen, M.; Kallblad, P.; Nystrom, S.; Wallberg, H.; Danielson, U.H. Identification of MMP-12 inhibitors by using biosensor-based screening of a fragment library. J. Med. Chem., 2008, 51, 3449-3459.
130. Fischer, M.; Hubbard, R.E. Fragment-based ligand discovery. Mol. Interv., 2009, 9, 22-30.
131. Kuglstatter, A.; Stahl, M.; Peters, J.U.; Huber, W.; Stihle, M.; Schlatter, D.; Benz, J.; Ruf, A.; Roth, D.; Enderle, T.; Hennig, M. Tyramine fragment binding to BACE-1. Bioorg. Med. Chem. Lett., 2008, 18, 1304-1307.
132. Antonysamy, S.S.; Aubol, B.; Blaney, J.; Browner, M.F.; Giannetti, A.M.; Harris, S.F.; Hebert, N.; Hendle, J.; Hopkins, S.; Jefferson, E.; Kissinger, C.; Leveque, V.; Marciano, D.; McGee, E.; Najera, I.; Nolan, B.; Tomimoto, M.; Torres, E.; Wright, T. Fragmentbased discovery of hepatitis C virus NS5b RNA polymerase inhibitors. Bioorg. Med. Chem. Lett., 2008, 18, 2990-2995.
133. Giannetti, A.M.; Koch, B.D.; Browner, M.F. Surface plasmon resonance based assay for the detection and characterization of promiscuous inhibitors. J. Med. Chem., 2008, 51, 574-580.
134. Neumann, T.; Junker, H.D.; Schmidt, K.; Sekul, R. SPR-based fragment screening: advantages and applications. Curr. Top. Med. Chem., 2007, 7, 1630-1642.
135. Heim-Riether, A.; Taylor, S.J.; Liang, S.; Gao, D.A.; Xiong, Z.; Michael August, E.; Collins, B.K.; Farmer, B.T., 2nd; Haverty, K.; Hill-Drzewi, M.; Junker, H.D.; Mariana Margarit, S.; Moss, N.; Neumann, T.; Proudfoot, J.R.; Keenan, L.S.; Sekul, R.; Zhang, Q.; Li, J.; Farrow, N.A. Improving potency and selectivity of a new class of non-Zn-chelating MMP-13 inhibitors. Bioorg. Med. Chem. Lett., 2009, 19, 5321-5324.
136. Neumann, T.; Junker, H.D.; Keil, O.; Burkert, K.; Ottleben, H.; Gamer, J.; Sekul, R.; Deppe, H.; Feurer, A.; Tomandl, D.; Metz, G. Discovery of thrombin inhibitor fragments from chemical microarray screening. Lett. Drug Des. Discov., 2005, 2, 590-594.
137. Bulat, S.; Bosio, S.; Papadopoulos, M.A.; Cerezo-Galvez, S.; Grabowski, E.; Rosenbaum, C.; Matassa, V.G.; Ott, I.; Metz, G.; Schamberger, J.; Sekul, R.; Feurer, A. Design and Discovery of Novel, Potent Pyrazinone-Based Thrombin Inhibitors With a Solubilizing Amino P-1-P-2-Linker. Lett. Drug Des. Discov., 2006, 3, 289-292.
138. Freire, E. Isothermal titration calorimetry: controlling binding forces in lead optimization. Drug Discov. Today Technol., 2004, 1, 295-299.
139. Holdgate, G.A.; Fisher, S.; Ward, W.H. The Application of Isothermal Titration Calorimetry to Drug Discovery In Biocalorimetry 2; Ladbury, J.E., Doyle, M.L., Eds. John Wiley: Chichester, 2004, 59.
140. Ladbury, J.E. Application of isothermal titration calorimetry in the biological sciences: things are heating up! Biotechniques, 2004, 37, 885-887.
141. Todd, M.J.; Luque, I.; Velazquez-Campoy, A.; Freire, E. Thermodynamic basis of resistance to HIV-1 protease inhibition: calorimetric analysis of the V82F/I84V active site resistant mutant. Biochemistry, 2000, 39, 11876-11883.
142. Velazquez-Campoy, A.; Kiso, Y.; Freire, E. The binding energetics of first and second-generation HIV-1 protease inhibitors: implications for drug design. Arch. Biochem. Biophys., 2001, 390, 169-175.
143. Breslow, R.; Belvedere, S.; Gershell, L.; Leung, D. The chelate effect in binding, catalysis, and chemotherapy. Pure Appl. Chem., 2000, 72, 333.
144. Jencks, W.P. On the attribution and additivity of binding energies. Proc. Natl. Acad. Sci. U.S.A., 1981, 78, 4046-4050.
145. Turnbull, W.B.; Precious, B.L.; Homans, S.W. Dissecting the cholera toxin-ganglioside GM1 interaction by isothermal titration calorimetry. J. Am. Chem. Soc., 2004, 126, 1047-1054.
146. Merritt, E.A.; Sarfaty, S.; van den Akker, F.; L'Hoir, C.; Martial, J.A.; Hol, W.G. Crystal structure of cholera toxin B-pentamer bound to receptor GM1 pentasaccharide. Protein Sci., 1994, 3, 166-175.
147. Freire, E. A thermodynamic approach to the affinity optimization of drug candidates. Chem. Biol. Drug Des., 2009, 74, 468-472.
148. Janin, J. Angstroms and calories Structure, 1997, 5, 473-479.
149. Hubbard, R.E. Can drugs be designed? Curr. Opin. Biotechnol., 1997, 8, 696-700.
150. Davis, A.M.; Teague, S.J. Hydrogen bonding, hydrophobic interactions, and failure of the rigid receptor hypothesis. Angew. Chem., 1999, 38, 736-749.
151. Ayala, Y.M.; Vindigni, A.; Nayal, M.; Spolar, R.S.; Record, M.T., Jr.; Di Cera, E. Thermodynamic investigation of hirudin binding to the slow and fast forms of thrombin: evidence for folding transitions in the inhibitor and protease coupled to binding. J. Mol. Biol., 1995, 253, 787-798.
152. Zhao, Y.; Halpert, J.R. Structure-function analysis of cytochromes P450 2B. Biochim.Biophys. Acta, 2007, 1770, 402-412.
153. Ward, W.H.; Holdgate, G.A. Isothermal titration calorimetry in drug discovery. Prog. Med. Chem., 2001, 38, 309-376.
154. Holdgate, G.A.; Tunnicliffe, A.; Ward, W.H.; Weston, S.A.; Rosenbrock, G.; Barth, P.T.; Taylor, I.W.; Pauptit, R.A.; Timms, D. The entropic penalty of ordered water accounts for weaker binding of the antibiotic novobiocin to a resistant mutant of DNA gyrase: a thermodynamic and crystallographic study. Biochemistry, 1997, 36, 9663-9673.
155. Ganem, B.; Li, Y.-T.; Henion, J.D. Detection of noncovalent receptor-ligand complexes by mass spectrometry. J. Am. Chem. Soc., 1991, 113, 6294-6296.
156. Hofstadler, S.A.; Griffey, R.H. Analysis of noncovalent complexes of DNA and RNA by mass spectrometry. Chem. Rev., 2001, 101, 377-390.
157. Swayze, E.E.; Jefferson, E.A.; Sannes-Lowery, K.A.; Blyn, L.B.; Risen, L.M.; Arakawa, S.; Osgood, S.A.; Hofstadler, S.A.; Griffey, R.H. SAR by MS: a ligand based technique for drug lead discovery against structured RNA targets. J. Med. Chem., 2002, 45, 3816-3819.
158. He, Y.; Yang, J.; Wu, B.; Robinson, D.; Sprankle, K.; Kung, P.P.; Lowery, K.; Mohan, V.; Hofstadler, S.; Swayze, E.E.; Griffey, R. Synthesis and evaluation of novel bacterial rRNA-binding benzimidazoles by mass spectrometry. Bioorg. Med. Chem. Lett., 2004, 14, 695-699.
159. Erlanson, D.A. Fragment-based lead discovery: a chemical update. Curr. Opin. Biotechnol., 2006, 17, 643-652.
160. Seth, P.P.; Miyaji, A.; Jefferson, E.A.; Sannes-Lowery, K.A.; Osgood, S.A.; Propp, S.S.; Ranken, R.; Massire, C.; Sampath, R.; Ecker, D.J.; Swayze, E.E.; Griffey, R.H. SAR by MS: discovery of a new class of RNA-binding small molecules for the hepatitis C virus: internal ribosome entry site IIA subdomain. J. Med. Chem., 2005, 48, 7099-7102.
161. Ockey, D.A.; Dotson, J.L.; Struble, M.E.; Stults, J.T.; Bourell, J.H.; Clark, K.R.; Gadek, T.R. Structure-activity relationships by mass spectrometry: identification of novel MMP-3 inhibitors. Bioorg. Med. Chem., 2004, 12, 37-44.
162. Ockey, D.A.; Gadek, T.R. Discovery of novel PTP1b inhibitors. Bioorg. Med. Chem. Lett., 2004, 14, 389-391.
163. Griffey, R.H.; Sannes-Lowery, K.A.; Drader, J.J.; Mohan, V.; Swayze, E.E.; Hofstadler, S.A. Characterization of low-affinity complexes between rna and small molecules using electrospray ionization mass spectrometry. J. Am. Chem. Soc., 2000, 122, 9933-9938.
164. Griffey, R.H.; Hofstadler, S.A.; Sannes-Lowery, K.A.; Ecker, D.J.; Crooke, S.T. Determinants of aminoglycoside-binding specificity for rRNA by using mass spectrometry. Proc. Natl. Acad. Sci. U.S.A., 1999, 96, 10129-10133.
165. Sannes-Lowery, K.A.; Griffey, R.H.; Hofstadler, S.A. Measuring dissociation constants of RNA and aminoglycoside antibiotics by electrospray ionization mass spectrometry. Anal. Biochem., 2000, 280, 264-271.
166. Strupat, K.; Sagi, D.; Peter-Katalinic, J.; Bonisch, H.; Schafer, G. Oligomerization and substrate binding studies of the adenylate kinase from Sulfolobus acidocaldarius by matrix-assisted laser desorption/ionization mass spectrometry Analyst, 2000, 125, 563.
167. Woods, A.S.; Buchsbaum, J.C.; Worrall, T.A.; Berg, J.M.; Cotter, R.J. Matrix-assisted laser desorption/ionization of noncovalently bound compounds. Anal. Chem., 1995, 67, 4462-4465.
168. Erlanson, D.A.; Wells, J.A.; Braisted, A.C. Tethering: fragmentbased drug discovery. Annu. Rev. Biophys. Biomol. Struct., 2004, 33, 199-223.
169. Erlanson, D.A.; Hansen, S.K. Making drugs on proteins: sitedirected ligand discovery for fragment-based lead assembly. Curr. Opin. Chem. Biol., 2004, 8, 399-406.
170. Erlanson, D.A.; Braisted, A.C.; Raphael, D.R.; Randal, M.; Stroud, R.M.; Gordon, E.M.; Wells, J.A. Site-directed ligand discovery. Proc. Natl. Acad. Sci. U.S.A., 2000, 97, 9367-9372.
171. Braisted, A.C.; Oslob, J.D.; Delano, W.L.; Hyde, J.; McDowell, R.S.; Waal, N.; Yu, C.; Arkin, M.R.; Raimundo, B.C. Discovery of a potent small molecule IL-2 inhibitor through fragment assembly. J. Am. Chem. Soc., 2003, 125, 3714-3715.
172. Webb, M.E.; Stephens, E.; Smith, A.G.; Abell, C. Rapid screening by MALDI-TOF mass spectrometry to probe binding specificity at enzyme active sites. Chem. Commun. (Camb), 2003, 2416-2417.
173. Erlanson, D.A.; Lam, J.W.; Wiesmann, C.; Luong, T.N.; Simmons, R.L.; DeLano, W.L.; Choong, I.C.; Burdett, M.T.; Flanagan, W.M.; Lee, D.; Gordon, E.M.; O'Brien, T. In situ assembly of enzyme inhibitors using extended tethering. Nat. Biotechnol., 2003, 21, 308-314.
174. O'Brien, T.; Fahr, B.T.; Sopko, M.M.; Lam, J.W.; Waal, N.D.; Raimundo, B.C.; Purkey, H.E.; Pham, P.; Romanowski, M.J. Structural analysis of caspase-1 inhibitors derived from Tethering. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun, 2005, 61, 451
175. Cancilla, M.T.; He, M.M.; Viswanathan, N.; Simmons, R.L.; Taylor, M.; Fung, A.D.; Cao, K.; Erlanson, D.A. Discovery of an Aurora kinase inhibitor through site-specific dynamic combinatorial chemistry. Bioorg. Med. Chem. Lett., 2008, 18, 3978-3981.
176. Khandekar, S.S.; Feng, B.; Yi, T.; Chen, S.; Laping, N.; Bramson, N. A liquid chromatography/mass spectrometry-based method for the selection of ATP competitive kinase inhibitors. J. Biomol. Screen, 2005, 10, 447-455.
177. Klages, J.; Coles, M.; Kessler, H. NMR-based screening: a powerful tool in fragment-based drug discovery. Analyst, 2007, 132, 693-705.
178. Stockman, B.J.; Dalvit, C. NMR screening techniques in drug discovery and drug design. Prog. Nucl. Magn. Reson. Spectrosc., 2002, 41, 187-231.
179. Pellecchia, M.; Bertini, I.; Cowburn, D.; Dalvit, C.; Giralt, E.; Jahnke, W.; James, T.L.; Homans, S.W.; Kessler, H.; Luchinat, C.; Meyer, B.; Oschkinat, H.; Peng, J.; Schwalbe, H.; Siegal, G. Perspectives on NMR in drug discovery: a technique comes of age. Nat. Rev. Drug Discov., 2008, 7, 738-745.
180. Meyer, B.; Peters, T. NMR Spectroscopy techniques for screening and identifying ligand binding to protein receptors. Angew. Chem. Int. Edit., 2003, 42, 864-890.
181. Zartler, E.R.; Shapiro, M.J. Fragonomics: fragment-based drug discovery. Curr. Opin. Chem. Biol., 2005, 9, 366-370.
182. Hajduk, P.J.; Greer, J. A decade of fragment-based drug design: strategic advances and lessons learned. Nat. Rev. Drug Discov., 2007, 6, 211-219.
183. Jahnke, W. Perspectives of biomolecular NMR in drug discovery: the blessing and curse of versatility. J. Biomol. NMR, 2007, 39, 87-90.
184. Jhoti, H.; Cleasby, A.; Verdonk, M.; Williams, G. Fragment-based screening using X-ray crystallography and NMR spectroscopy. Curr. Opin. Chem. Biol., 2007, 11, 485-493.
185. Betz, M.; Saxena, K.; Schwalbe, H. Biomolecular NMR: a chaperone to drug discovery. Curr. Opin. Chem. Biol., 2006, 10, 219-225.
186. Szczepankiewicz, B.G.; Liu, G.; Hajduk, P.J.; Abad-Zapatero, C.; Pei, Z.H.; Xin, Z.L.; Lubben, T.H.; Trevillyan, J.M.; Stashko, M.A.; Ballaron, S.J.; Liang, H.; Huang, F.; Hutchins, C.W.; Fesik, S.W.; Jirousek, M.R. Discovery of a potent, selective protein tyrosine phosphatase 1B inhibitor using a linked-fragment strategy. J. Am. Chem. Soc., 2003, 125, 4087-4096.
187. Wang, B.; Raha, K.; Merz, K.M. Pose scoring by NMR. J. Am. Chem. Soc., 2004, 126, 11430-11431.
188. McCoy, M.A.; Wyss, D.F. Alignment of weakly interacting molecules to protein surfaces using simulations of chemical shift perturbations. J. Biomol. NMR, 2000, 18, 189-198.
189. Hajduk, P.J.; Huth, J.R.; Fesik, S.W. Druggability indices for protein targets derived from NMR-based screening data. J. Med. Chem., 2005, 48, 2518-2525.
190. Pervushin, K.; Riek, R.; Wider, G.; Wuthrich, K. Attenuated T2 relaxation by mutual cancellation of dipole-dipole coupling and chemical shift anisotropy indicates an avenue to NMR structures of very large biological macromolecules in solution. Proc. Natl. Acad. Sci. U.S.A., 1997, 94, 12366-12371.
191. Feliz, M.; Garcia, J.; Aragon, E.; Pons, M. Fast 2D NMR ligand screening using Hadamard spectroscopy. J. Am. Chem. Soc., 2006, 128, 7146-7147.
192. Mayer, M.; Meyer, B. Characterization of ligand binding by saturation transfer difference NMR spectroscopy. Angew. Chem. Int. Edit., 1999, 38, 1784-1788.
193. Blume, A.; Benie, A.J.; Stolz, F.; Schmidt, R.R.; Reutter, W.; Hinderlich, S.; Peters, T. Characterization of ligand binding to the bifunctional key enzyme in the sialic acid biosynthesis by NMR-I. Investigation of the UDP-GlcNAc 2-epimerase functionality. J. Biol. Chem., 2004, 279, 55715-55721.
194. Dalvit, C.; Pevarello, P.; Tato, M.; Veronesi, M.; Vulpetti, A.; Sundstrom, M. Identification of compounds with binding affinity to proteins via magnetization transfer from bulk water. J. Biomol. NMR, 2000, 18, 65-68.
195. Ludwig, C.; Michiels, P.J.A.; Wu, X.; Kavanagh, K.L.; Pilka, E.; Jansson, A.; Oppermann, U.; Gunther, U.L. SALMON: Solvent accessibility, ligand binding, and mapping of ligand orientation by NMR Spectroscopy. J. Med. Chem., 2008, 51, 1-3.
196. Dalvit, C.; Fogliatto, G.; Stewart, A.; Veronesi, M.; Stockman, B. WaterLOGSY as a method for primary NMR screening: practical aspects and range of applicability. J. Biomol. NMR, 2001, 21, 349-359.
197. Post, C.B. Exchange-transferred NOE spectroscopy and bound ligand structure determination. Curr. Opin. Struct. Biol., 2003, 13, 581-588.
198. Vanwetswinkel, S.; Heetebrij, R.J.; van Duynhoven, J.; Hollander, J.G.; Filippov, D.V.; Hajduk, P.J.; Siegal, G. TINS, target immobilized NMR screening: An efficient and sensitive method for ligand discovery. Chem. Biol., 2005, 12, 207-216.
199. Marquardsen, T.; Hofmann, M.; Hollander, J.G.; Loch, C.M.P.; Kiihne, S.R.; Engelke, F.; Siegal, G. Development of a dual cell, flow-injection sample holder, and NMR probe for comparative ligand-binding studies. J. Magn. Reson., 2006, 182, 55-65.
200. Dalvit, C.; Ardini, E.; Flocco, M.; Fogliatto, G.P.; Mongelli, N.; Veronesi, M. A general NMR method for rapid, efficient, and reliable biochemical screening. J. Am. Chem. Soc., 2003, 125, 14620-14625.
201. Dalvit, C.; Fagerness, P.E.; Hadden, D.T.A.; Sarver, R.W.; Stockman, B.J. Fluorine-NMR experiments for high-throughput screening: Theoretical aspects, practical considerations, and range of applicability. J. Am. Chem. Soc., 2003, 125, 7696-7703.
202. Dalvit, C. Ligand and substrate-based F-19 NMR screening: Principles and applications to drug discovery. Prog. Nucl. Magn. Reson. Spectrosc., 2007, 51, 243-I.
203. Manzenrieder, F.; Frank, A.O.; Kessler, H. Phosphorus NMR spectroscopy as a versatile tool for compound library screening. Angew. Chem. Int. Edit., 2008, 47, 2608-2611.
204. Dalvit, C.; Mongelli, N.; Papeo, G.; Giordano, P.; Veronesi, M.; Moskau, D.; Kummerle, R. Sensitivity improvement in F-19 NMR-based screening experiments: Theoretical considerations and experimental applications. J. Am. Chem. Soc., 2005, 127, 13380-13385.
205. Papeo, G.; Giordano, P.; Brasca, M.G.; Buzzo, F.; Caronni, D.; Ciprandi, F.; Mongelli, N.; Veronesi, M.; Vulpetti, A.; Dalvit, C. Polyfluorinated amino acids for sensitive F-19 NMR-based screening and kinetic measurements. J. Am. Chem. Soc., 2007, 129, 5665-5672.
206. Fattorusso, R.; Jung, D.W.; Crowell, K.J.; Forino, M.; Pellecchia, M. Discovery of a novel class of reversible non-peptide caspase inhibitors via a structure-based approach. J. Med. Chem., 2005, 48, 1649-1656.
207. Jahnke, W.; Floersheim, P.; Ostermeier, C.; Zhang, X.L.; Hemmig, R.; Hurth, K.; Uzunov, D.P. NMR reporter screening for the detection of high-affinity ligands. Angew. Chem. Int. Edit., 2002, 41, 3420-3423.
208. Dalvit, C. Theoretical analysis of the competition ligand-based NMR experiments and selected applications to fragment screening and binding constant measurements. Concepts Magn. Reson. Part A, 2008, 32A, 341-372.
209. Wang, Y.S.; Liu, D.J.; Wyss, D.F. Competition STD NMR for the detection of high-affinity ligands and NMR-based screening. Magn. Reson. Chem., 2004, 42, 485-489.
210. Dalvit, C.; Fasolini, M.; Flocco, M.; Knapp, S.; Pevarello, P.; Veronesi, M. NMR-based screening with competition water-ligand observed via gradient spectroscopy experiments: Detection of highaffinity ligands. J. Med. Chem., 2002, 45, 2610-2614.
211. Siriwardena, A.H.; Tian, F.; Noble, S.; Prestegard, J.H. A straightforward NMR-spectroscopy-based method for rapid library screening. Angew. Chem. Int. Edit., 2002, 41, 3454-3457.
212. Dalvit, C.; Flocco, M.; Knapp, S.; Mostardini, M.; Perego, R.; Stockman, B.J.; Veronesi, M.; Varasi, M. High-throughput NMRbased screening with competition binding experiments. J. Am. Chem. Soc., 2002, 124, 7702-7709.
213. van Dongen, M.J.P.; Uppenberg, J.; Svensson, S.; Lundback, T.; Akerud, T.; Wikstrom, M.; Schultz, J. Structure-based screening as applied to human FABP4: A highly efficient alternative to HTS for hit generation. J. Am. Chem. Soc., 2002, 124, 11874-11880.
214. Feher, K.; Groves, P.; Batta, G.; Jimenez-Barbero, J.; Muhle-Goll, C.; Kover, K.E. Competition saturation transfer difference experiments improved with isotope editing and filtering schemes in NMR-based screening. J. Am. Chem. Soc., 2008, 130, 17148-17153.
215. Dalvit, C.; Hadden, D.T.A.; Sarver, R.W.; Ho, A.M.; Stockman, B.J. Multi-selective one dimensional proton NMR experiments for rapid screening and binding affinity measurements. Comb. Chem. High Throughput Screening, 2003, 6, 445-453.
216. Stockman, B.J. 2-Fluoro-ATP as a versatile tool for 19F NMR-based activity screening. J. Am. Chem. Soc., 2008, 130, 5870-5871.
217. Sanchez-Pedregal, V.M.; Reese, M.; Meiler, J.; Blommers, M.J.J.; Griesinger, C.; Carlomagno, T. The INPHARMA method: Proteinmediated interligand NOEs for pharmacophore mapping. Angew. Chem. Int. Edit., 2005, 44, 4172-4175.
218. Fielding, L. NMR methods for the determination of protein-ligand dissociation constants. Prog. Nucl. Magn. Reson. Spectrosc., 2007, 51, 219-242.
219. Zhang, X.; Sanger, A.; Hemmig, R.; Jahnke, W. Ranking of High-Affinity Ligands by NMR Spectroscopy. Angew. Chem. Int. Ed. Engl., 2009, 48, 6691-6694.
220. Shortridge, M.D.; Hage, D.S.; Harbison, G.S.; Powers, R. Estimating Protein-Ligand Binding Affinity Using High-Throughput Screening by NMR. J. Comb. Chem., 2008, 10, 948-958.
221. Jahnke, W.; Rudisser, S.; Zurini, M. Spin label enhanced NMR screening. J. Am. Chem. Soc., 2001, 123, 3149-3150.
222. Jahnke, W.; Blommers, M.J.J.; Fernandez, C.; Zwingelstein, C.; Amstutz, R. Strategies for the NMR-based identification and optimization of allosteric protein kinase inhibitors. Chembiochem, 2005, 6, 1607-1610.
223. D'Silva, L.; Ozdowy, P.; Krajewski, M.; Rothweiler, U.; Singh, M.; Holak, T.A. Monitoring the effects of antagonists on proteinprotein interactions with NMR spectroscopy. J. Am. Chem. Soc., 2005, 127, 13220-13226.
224. Joshi, M.; Vargas, C.; Boisguerin, P.; Diehl, A.; Krause, G.; Schmieder, P.; Moelling, K.; Hagen, V.; Schade, M.; Oschkinat, H. Discovery of low-molecular-weight ligands for the AF6 PDZ domain. Angew. Chem. Int. Edit., 2006, 45, 3790-3795.
225. Geschwindner, S.; Olsson, L.L.; Albert, J.S.; Deinum, J.; Edwards, P.D.; de Beer, T.; Folmer, R.H.A. Discovery of a novel warhead against beta-secretase through fragment-based lead generation. J. Med. Chem., 2007, 50, 5903-5911.
226. Johnson, E.C.; Feher, V.A.; Peng, J.W.; Moore, J.M.; Williamson, J.R. Application of NMR SHAPES screening to an RNA target. J. Am. Chem. Soc., 2003, 125, 15724-15725.
227. Bretonnet, A.S.; Jochum, A.; Walker, O.; Krimm, I.; Goekjian, P.; Marcillat, O.; Lancelin, J.M. NMR screening applied to the fragment-based generation of inhibitors of creatine kinase exploiting a new interaction proximate to the ATP binding site. J. Med. Chem., 2007, 50, 1865-1875.
228. Leslie, A.G.; Powell, H.R.; Winter, G.; Svensson, O.; Spruce, D.; McSweeney, S.; Love, D.; Kinder, S.; Duke, E.; Nave, C. Automation of the collection and processing of X-ray diffraction data-a generic approach. Acta Crystallogr. D Biol. Crystallogr., 2002, 58, 1924-1928.
229. Tickle, I.; Sharff, A.; Vinkovic, M.; Yon, J.; Jhoti, H. Highthroughput protein crystallography and drug discovery. Chem. Soc. Rev., 2004, 33, 558-565.
230. Davis, A.M.; St-Gallay, S.A.; Kleywegt, G.J. Limitations and lessons in the use of X-ray structural information in drug design. Drug Discov. Today, 2008, 13, 831-841.
231. Damm, K.L.; Carlson, H.A. Exploring experimental sources of multiple protein conformations in structure-based drug design. J. Am. Chem. Soc., 2007, 129, 8225-8235.
232. Evrard, G.X.; Langer, G.G.; Perrakis, A.; Lamzin, V.S. Assessment of automatic ligand building in ARP/wARP. Acta Crystallogr. D Biol. Crystallogr., 2007, 63, 108-117.
233. Oldfield, T.J. X-LIGAND: an application for the automated addition of flexible ligands into electron density. Acta Crystallogr. D Biol. Crystallogr., 2001, 57, 696-705.
234. Mooij, W.T.; Hartshorn, M.J.; Tickle, I.J.; Sharff, A.J.; Verdonk, M.L.; Jhoti, H. Automated protein-ligand crystallography for structure-based drug design. ChemMedChem, 2006, 1, 827-838.
235. Hartshorn, M.J.; Murray, C.W.; Cleasby, A.; Frederickson, M.; Tickle, I.J.; Jhoti, H. Fragment-based lead discovery using X-ray crystallography. J. Med. Chem., 2005, 48, 403-413.
236. Howard, N.; Abell, C.; Blakemore, W.; Chessari, G.; Congreve, M.; Howard, S.; Jhoti, H.; Murray, C.W.; Seavers, L.C.A.; van Montfort, R.L.M. Application of fragment screening and fragment linking to the discovery of novel thrombin inhibitors. J. Med. Chem., 2006, 49, 1346-1355.
237. Wyatt, P.G.; Woodhead, A.J.; Berdini, V.; Boulstridge, J.A.; Carr, M.G.; Cross, D.M.; Davis, D.J.; Devine, L.A.; Early, T.R.; Feltell, R.E.; Lewis, E.J.; McMenamin, R.L.; Navarro, E.F.; O'Brien, M.A.; O'Reilly, M.; Reule, M.; Saxty, G.; Seavers, L.C.A.; Smith, D.M.; Squires, M.S.; Trewartha, G.; Walker, M.T.; Woolford, A.J.A. Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based Xray crystallography and structure based drug design. J. Med. Chem., 2008, 51, 4986-4999.
238. Nienaber, V.L.; Richardson, P.L.; Klighofer, V.; Bouska, J.J.; Giranda, V.L.; Greer, J. Discovering novel ligands for macromolecules using X-ray crystallographic screening. Nat. Biotechnol., 2000, 18, 1105-1108.
239. Sanders, W.J.; Nienaber, V.L.; Lerner, C.G.; McCall, J.O.; Merrick, S.M.; Swanson, S.J.; Harlan, J.E.; Stoll, V.S.; Stamper, G.F.; Betz, S.F.; Condroski, K.R.; Meadows, R.P.; Severin, J.M.; Walter, K.A.; Magdalinos, P.; Jakob, C.G.; Wagner, R.; Beutel, B.A. Discovery of potent inhibitors of dihydroneopterin aldolase using crystaLEAD high-throughput X-ray crystallographic screening and structure-directed lead optimization. J. Med. Chem., 2004, 47, 1709-1718.
240. Bosch, J.; Robien, M.A.; Mehlin, C.; Boni, E.; Riechers, A.; Buckner, F.S.; Van Voorhis, W.C.; Myler, P.J.; Worthey, E.A.; DeTitta, G.; Luft, J.R.; Lauricella, A.; Gulde, S.; Anderson, L.A.; Kalyuzhniy, O.; Neely, H.M.; Ross, J.; Earnest, T.N.; Soltis, M.; Schoenfeld, L.; Zucker, F.; Merritt, E.A.; Fan, E.; Verlinde, C.; Hol, W.G.J. Using fragment cocktail crystallography to assist inhibitor design of Trypanosoma brucei nucleoside 2-deoxyribosyltransferase. J. Med. Chem., 2006, 49, 5939-5946.
241. Tsai, J.; Lee, J.T.; Wang, W.; Zhang, J.; Cho, H.; Mamo, S.; Bremer, R.; Gillette, S.; Kong, J.; Haass, N.K.; Sproesser, K.; Li, L.; Smalley, K.S.M.; Fong, D.; Zhu, Y.L.; Marimuthu, A.; Nguyen, H.; Lam, B.; Liu, J.; Cheung, I.; Rice, J.; Suzuki, Y.; Luu, C.; Settachatgul, C.; Shellooe, R.; Cantwell, J.; Kim, S.H.; Schlessinger, J.; Zhang, K.Y.J.; West, B.L.; Powell, B.; Habets, G.; Zhang, C.; Ibrahim, P.N.; Hirth, P.; Artis, D.R.; Herlyn, M.; Bollag, G. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl. Acad. Sci. U.S.A., 2008, 105, 3041-3046.
242. Card, G.L.; Blasdel, L.; England, B.P.; Zhang, C.; Suzuki, Y.; Gillette, S.; Fong, D.; Ibrahim, P.N.; Artis, D.R.; Bollag, G.; Milburn, M.V.; Kim, S.H.; Schlessinger, J.; Zhang, K.Y.J. A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design. Nat. Biotechnol., 2005, 23, 201-207.
243. de Kloe, G.E.; Bailey, D.; Leurs, R.; de Esch, I.J. Transforming fragments into candidates: small becomes big in medicinal chemistry. Drug Discov. Today, 2009, 14, 630-646.
244. Chessari, G.; Woodhead, A.J. From fragment to clinical candidate-a historical perspective. Drug Discov. Today, 2009, 14, 668-675.
245. Barker, J.; Courtney, S.; Hesterkamp, T.; Ullmann, D.; Whittaker, M. Fragment screening by biochemical assay. Expert Opin. Drug Discov., 2006, 1, 225-236.
246. Leach, A.R.; Hann, M.M.; Burrows, J.N.; Griffen, E.J. Fragment screening: an introduction. Mol. Biosyst., 2006, 2, 430-446.